Zacks Investment Research Lowers Vascular Biogenics (VBLT) to Hold
According to Zacks, “Vascular Biogenics Ltd. is a clinical stage biotechnology company. It is focused on the discovery, development and commercialization of treatments for cancer and immune-inflammatory diseases. Its lead oncology candidate VB-111, is a gene-based biologic which is in Phase II clinical trials for the treatment of recurrent glioblastoma, an aggressive form of brain cancer. It is also developing VB-201, an oral small molecule that is in Phase II clinical trials for the treatment psoriasis and ulcerative colitis. Vascular Biogenics Ltd. is headquartered in Or Yehuda, Israel. “
Other equities research analysts have also issued reports about the company. Chardan Capital reaffirmed a neutral rating on shares of Vascular Biogenics in a research report on Wednesday, March 13th. HC Wainwright reaffirmed a buy rating and set a $3.00 target price on shares of Vascular Biogenics in a research report on Thursday, May 16th. Finally, ValuEngine lowered Vascular Biogenics from a hold rating to a sell rating in a research report on Wednesday, May 1st.
Vascular Biogenics (NASDAQ:VBLT) last announced its earnings results on Wednesday, May 15th. The biopharmaceutical company reported ($0.12) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.06) by ($0.06). The company had revenue of $0.22 million for the quarter, compared to analyst estimates of $2.30 million. Vascular Biogenics had a negative return on equity of 31.69% and a negative net margin of 2,724.02%. On average, research analysts forecast that Vascular Biogenics will post -0.52 EPS for the current year.
Hedge funds have recently modified their holdings of the company. Menta Capital LLC purchased a new position in shares of Vascular Biogenics during the first quarter valued at $35,000. RBF Capital LLC purchased a new position in shares of Vascular Biogenics during the fourth quarter valued at $353,000. First Republic Investment Management Inc. grew its holdings in shares of Vascular Biogenics by 7.4% during the first quarter. First Republic Investment Management Inc. now owns 145,000 shares of the biopharmaceutical company’s stock valued at $220,000 after buying an additional 10,000 shares in the last quarter. Morgan Stanley grew its holdings in shares of Vascular Biogenics by 19.7% during the first quarter. Morgan Stanley now owns 277,112 shares of the biopharmaceutical company’s stock valued at $421,000 after buying an additional 45,552 shares in the last quarter. Finally, Acadian Asset Management LLC grew its holdings in shares of Vascular Biogenics by 272.3% during the first quarter. Acadian Asset Management LLC now owns 59,427 shares of the biopharmaceutical company’s stock valued at $90,000 after buying an additional 43,466 shares in the last quarter. Institutional investors and hedge funds own 6.85% of the company’s stock.
About Vascular Biogenics
Vascular Biogenics Ltd., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of treatments for cancer. The company's program is based on its proprietary vascular targeting system platform technology, which utilizes genetically targeted therapy to destroy newly formed or angiogenic blood vessels.
Featured Story: How to calculate the annual rate of depreciation
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Vascular Biogenics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vascular Biogenics and related companies with MarketBeat.com's FREE daily email newsletter.